Related Experiment Video
Updated: Jul 9, 2025

The Soft Agar Colony Formation Assay
Published on: October 27, 2014
Oncogenic KRAS effector USP13 promotes metastasis in non-small cell lung cancer through deubiquitinating β-catenin
Yanguan Guo1, Jiaxin Tian2, Yongjian Guo2
1School of Biopharmacy, China Pharmaceutical University, Nanjing 211198, P.R. China; Department of General Surgery and Department of Thoracic Surgery, The First Affiliated Hospital of Jinan University, Guangzhou 510632, P.R. China.
Abstract:
KRAS mutations are frequently detected in non-small cell lung cancers (NSCLCs). Although covalent KRASG12C inhibitors have been developed to treat KRASG12C-mutant cancers, effective treatments are still lacking for other KRAS-mutant NSCLCs. Thus, identifying a KRAS effector that confers poor prognosis would provide an alternative strategy for the treatment of KRAS-driven cancers. Here, we show that KRAS drives expression of deubiquitinase USP13 through Ras-responsive element-binding protein 1 (RREB1). Elevated USP13 promotes KRAS-mutant NSCLC metastasis, which is associated with poor prognosis in NSCLC patients. Mechanistically, USP13 interacts with and removes the K63-linked polyubiquitination of β-catenin at lysine 508, which enhances the binding between β-catenin and transcription factor TCF4. Importantly, we identify 2-methoxyestradiol as an effective inhibitor for USP13 from a natural compound library, and it could potently suppress the metastasis of KRAS-mutant NSCLC cells in vitro and in vivo. These findings identify USP13 as a therapeutic target for metastatic NSCLC with KRAS mutations.
Insights
Researchers identified USP13 as a key driver of metastasis in KRAS-mutant non-small cell lung cancer (NSCLC). Targeting USP13 with 2-methoxyestradiol offers a potential new treatment strategy for advanced NSCLC patients.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- KRAS mutations are common in non-small cell lung cancer (NSCLC), but treatments for many KRAS-mutant NSCLCs remain limited.
- Developing targeted therapies requires understanding KRAS effectors that drive poor prognosis.
Purpose of the Study:
- To identify novel therapeutic targets for KRAS-mutant NSCLC.
- To investigate the role of KRAS-driven effectors in NSCLC metastasis.
Main Methods:
- Investigated the role of deubiquitinase USP13 in KRAS-driven NSCLC.
- Examined the mechanism of USP13 in regulating β-catenin and TCF4 interaction.
- Screened a natural compound library for USP13 inhibitors.
Main Results:
- KRAS signaling upregulates USP13 expression via RREB1.
- Elevated USP13 promotes NSCLC metastasis and is linked to poor patient prognosis.
- USP13 deubiquitinates β-catenin, enhancing its binding to TCF4.
- 2-methoxyestradiol effectively inhibits USP13 and suppresses NSCLC metastasis in vitro and in vivo.
Conclusions:
- USP13 is a KRAS effector that promotes metastasis in NSCLC.
- USP13 is a potential therapeutic target for KRAS-mutant metastatic NSCLC.
- 2-methoxyestradiol shows promise as a treatment for KRAS-mutant NSCLC.
Related Concept Videos
Abnormal Proliferation
Catenins
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the...
Non-Canonical Wnt Signaling Pathways
Canonical Wnt Signaling Pathway
Destabilization of Microtubules
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

